What Pharma Needs Next

Extracting Real Value During AI’s ‘Gold Rush’

In an episode you won’t want to miss, Florian Schnappauf deep dives into generative AI with David Simpson of AstraZeneca who has been experimenting, piloting, and scaling AI use cases with sales reps across markets. David shares why users now have a different mindset and the direction that sales assistants may be going in the future. He also explains his view that a common data language is fundamental to maximizing the value of AI.

Preparing for a Faster Trial-to-Treatment Pathway

Pharmaphorum’s Nicole Raleigh interviews Chris Moore, president of Veeva Europe, on trends shaping commercial life sciences. Chris highlights AI’s potential use cases, the need for caution, and how commercial and medical leaders are overcoming access challenges to accelerate treatment pathways.

Preparing for a Launch: Pharma's High-Stakes Gamble

Veeva's Florian Schnappauf speaks to Andy Eeckhout of ADVANZ PHARMA about ensuring launch success. Preparing for a launch is a high-stakes gamble for all biopharma companies, particularly those focused on rare diseases. Andy explains how ADVANZ uses data to prepare for a launch, scale across multiple markets, and help MSLs get up-to-speed quickly for an in-depth scientific discussion with experts.

The Problem of Plenty in Life Sciences

Despite major advances in recent years, it is still too difficult for biopharma field teams to bring together all relevant information to serve HCPs. Florian Schnappauf and Rakesh Vashishta discuss whether the industry asks too much of its field teams, how we can avoid drowning in data, and the changing role of reps to orchestrators of the customer experience.

Navigating the New Medical Affairs Landscape: Data, Impact, and the Evolving MSL Role

In this episode, Christoph Bug, VP Global Medical at Veeva, discusses the evolving role of medical affairs with industry experts. They explore how medical teams adapt to the growing demand for scientific exchange and how medical affairs can become a more strategic, data-driven decision-making organization.